| Submission declined on 5 December 2024 by Timtrent (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies. This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: All inline links should be removed, please, and turned into references if appropriate, Wikilinks, or external links in a section so named. See Wikipedia:External links. There should be no links pointing to external sources until those in the 'References' section (with the exception of one optional link in any infobox).These are post start of internet references. Pease find online versions 🇺🇦 FiddleTimtrent FaddleTalk to me 🇺🇦 22:31, 5 December 2024 (UTC)
Wegovy ( semaglutide )
editWegovy is a prescription medication developed by Novo Nordisk for chronic weight management. It is a form of semaglutide, a GLP-1 receptor agonist, approved by the U.S. Food and Drug Administration (FDA) specifically for weight loss.[1][2]. Wegovy has shown promising results for individuals struggling with obesity or weight-related health conditions[3].
Wegovy is prescribed for adults who meet the following criteria:
- A Body Mass Index (BMI) of 30 or higher (classified as obese), or
- A BMI of 27 or higher (overweight) with at least one associated health condition, such as type 2 diabetes or hypertension[4][5].
In clinical studies, patients using Wegovy in conjunction with a reduced-calorie diet and increased physical activity experienced an average weight loss of approximately 15% of their body weight[6][7]. This significant reduction highlights its effectiveness as part of a comprehensive weight management plan.
How It Works
editWegovy works by:
Cost of Wegovy
editThe cost of Wegovy varies depending on insurance coverage and geographic location. In the United States, the retail price typically ranges from $1,300 to $1,500 per month without insurance[10][11]. However, financial assistance programs provided by Novo Nordisk may help eligible patients afford the medication[12].
Insurance coverage is often limited, and patients may need to consult their providers to determine eligibility for reimbursement or co-pay programs[13][14]
- ^ FDA Approval Announcement for Wegovy (fda.gov)
- ^ Novo Nordisk Product Information for Wegovy (novonordisk.com)
- ^ Clinical Trials Data for Semaglutide in Weight Loss (nih.gov)
- ^ BMI Guidelines for Weight Loss Medications (who.int)
- ^ Obesity and Overweight Factsheet (cdc.gov)
- ^ Wegovy Clinical Trial Results on Weight Loss (nejm.org).
- ^ Semaglutide for Chronic Weight Management (thelancet.com)
- ^ Mechanism of GLP-1 Receptor Agonists (sciencedirect.com)
- ^ Effects of GLP-1 on Appetite Regulation (pubmed.ncbi.nlm.nih.gov)
- ^ U.S. Retail Pricing Data for Wegovy (goodrx.com)
- ^ Pricing Overview for Wegovy in the United States (forbes.com)
- ^ Novo Nordisk Assistance Programs for Wegovy (novonordisk-us.com)
- ^ Insurance Coverage Challenges for Wegovy (healthaffairs.org)
- ^ Policy Changes on Obesity Drug Reimbursement (cms.gov)